Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
MannKind Corp said results of two late-stage studies showed that its experimental diabetes therapy was more effective than injected insulin and oral treatments, sending its shares up 30 percent in premarket trading.
The drug-device combination, called Afrezza, consists of insulin powder loaded into a cartridge and used as an inhaler. It is designed to treat adult patients with Type 1 and Type 2 diabetes.
Afrezza is the flagship product of MannKind, whose shares have risen nearly 50 percent over the past three months in anticipation of positive data from the two trials.
http://uk.reuters.com/article/2013/08/14/us-mannkind-study-idUKBRE97D0GG20130814
The drug-device combination, called Afrezza, consists of insulin powder loaded into a cartridge and used as an inhaler. It is designed to treat adult patients with Type 1 and Type 2 diabetes.
Afrezza is the flagship product of MannKind, whose shares have risen nearly 50 percent over the past three months in anticipation of positive data from the two trials.
http://uk.reuters.com/article/2013/08/14/us-mannkind-study-idUKBRE97D0GG20130814